ReviewDrug design, development and therapy2026
Remodeling the Stroma: The Role of ncRNAs in Cancer-Associated Fibroblasts and Therapeutic Implications for Digestive Tumors.
Review in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The crosstalk between cancer-associated fibroblasts (CAFs) and tumor cells presents a formidable barrier to treating digestive malignancies, yet the molecular syntax governing this interaction is often overlooked. Recent studies have highlighted the indispensable function of non-coding RNAs (ncRNAs), which act not merely as bystanders but as architects of stromal remodeling. Here, we dissect how ncRNAs dictate the heterogeneity and function of CAFs, regulating fibroblast activation, metastatic niche formation, drug resistance, and metabolic reprogramming. We further examine how the exosomal transfer of ncRNAs reshapes the immune landscape, engineering a tumor-permissive microenvironment. Current clinical observations indicate, however, that indiscriminate depletion of CAFs is often counterproductive, underscoring the necessity of "stromal normalization." Targeting specific ncRNA master regulators to reprogram activated CAFs to a quiescent state-rather than destroying them-provides robust mechanistic support for the stromal normalization paradigm previously proposed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.